Drugs / NDBR 101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03867162 | Jun → Dec 2021 | tularemia | U.S. Army Medical Research and Development Command | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00787826 | Aug 2009 → Nov 2019 | tularemia | U.S. Army Medical Research and Development Command | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NDBR 101 | “Phase 2 Open-Label Safety and Immunogenicity Study of Tularemia Vaccine, Live, Attenuated (NDBR 101, Lot 4) in Adult Subjects at Risk of Exposure to Tularemia Bacteria” NCT03867162 ↗1“To assess the safety of live F. tularensis vaccine NDBR 101.” NCT00787826 ↗ |
| Known as | Tularemia Vaccine, Live, Attenuated | “Phase 2 Open-Label Safety and Immunogenicity Study of Tularemia Vaccine, Live, Attenuated (NDBR 101, Lot 4) in Adult Subjects at Risk of Exposure to Tularemia Bacteria” NCT03867162 ↗ |
| Route | Other | “will be administered percutaneously with a bifurcated needle” NCT00787826 ↗ |